VIEMED HEALTHCARE, INC.(VMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #779 of 2,962 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
VMD Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for VIEMED HEALTHCARE, INC. (VMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VMD at 61.5/100 on a 32-signal composite quality model, placing it at rank #779 of 2,962 stocks — the top half of the AI-ranked universe. VMD scores in the top quartile across earnings quality (93.3), revenue growth (83.2), balance sheet strength (79.0). Areas of concern include revenue scale (29.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), VIEMED HEALTHCARE, INC. reports quarterly revenue of $78.1M, net income of $2.8M, an operating margin of 5.7%. Top institutional holders of VMD by reported 13-F value include BlackRock, Forager Capital Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. VMD trades on the Nasdaq exchange and files with the SEC under CIK 1729149. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VIEMED HEALTHCARE, INC. directly from SEC EDGAR. VIEMED HEALTHCARE, INC.'s 13F Pro composite quality score has ranged between 31 and 73 since 2021, currently 61.5 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$78.1M
Net Income
Q2 2026
$2.8M
Free Cash Flow
Q2 2026
$7.4M
Operating Margin
Q2 2026
5.7%
ROIC
Q2 2026
11.8%
D/E Ratio
Q2 2026
0.05
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+20.5% YoYNet Income
+32.6% YoYOperating Income
+28.2% YoYEPS (Diluted)
+32.1% YoYTotal Assets
+12.5% YoYTotal Debt
+209.7% YoYOp. Cash Flow
+32.8% YoYFree Cash Flow
+805.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $270.3M +20.5% | $224.3M +22.5% | $183.0M +31.8% | $138.8M +18.6% | $117.1M -10.8% | $131.3M |
| Net Income | $14.9M +32.6% | $11.3M +10.0% | $10.2M +64.6% | $6.2M -31.8% | $9.1M -71.1% | $31.5M |
| Operating Income | $22.9M +28.2% | $17.9M +24.9% | $14.3M +73.7% | $8.3M -28.7% | $11.6M -56.8% | $26.8M |
| EPS (Diluted) | $0.37 +32.1% | $0.28 +12.0% | $0.25 +56.3% | $0.16 -27.3% | $0.22 -71.8% | $0.78 |
| Total Assets | $199.2M +12.5% | $177.1M +14.3% | $154.9M +32.3% | $117.0M -0.8% | $118.0M +4.8% | $112.6M |
| Total Debt | $12.4M +209.7% | $4.0M -43.5% | $7.1M | $0.00 -100.0% | $5.8M -24.2% | $7.6M |
| Operating Cash Flow | $51.9M +32.8% | $39.1M -13.5% | $45.2M +62.9% | $27.7M +23.4% | $22.5M -35.9% | $35.1M |
| Free Cash Flow | $11.9M +805.2% | $1.3M -93.1% | $19.1M +294.2% | $4.8M +76.3% | $2.8M -87.5% | $22.1M |
Get alerted when VMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for VIEMED HEALTHCARE, INC. including:
Top Institutional Holders of VMD
BlackRock, Inc.
$54.6M4,788,307 shForager Capital Management, LLC
$24.4M2,141,184 shVANGUARD CAPITAL MANAGEMENT LLC
$15.1M1,321,676 shGOLDMAN SACHS GROUP INC
$13.9M1,222,534 shAMERIPRISE FINANCIAL INC
$11.5M1,006,195 shGEODE CAPITAL MANAGEMENT, LLC
$11.1M973,744 shARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$9.0M786,269 shSTATE STREET CORP
$8.7M762,097 shNantahala Capital Management, LLC
$7.2M632,445 shPANAGORA ASSET MANAGEMENT INC
$6.1M538,625 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $54.6M | 4,788,307 |
| Forager Capital Management, LLC | $24.4M | 2,141,184 |
| VANGUARD CAPITAL MANAGEMENT LLC | $15.1M | 1,321,676 |
| GOLDMAN SACHS GROUP INC | $13.9M | 1,222,534 |
| AMERIPRISE FINANCIAL INC | $11.5M | 1,006,195 |
| GEODE CAPITAL MANAGEMENT, LLC | $11.1M | 973,744 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $9.0M | 786,269 |
| STATE STREET CORP | $8.7M | 762,097 |
| Nantahala Capital Management, LLC | $7.2M | 632,445 |
| PANAGORA ASSET MANAGEMENT INC | $6.1M | 538,625 |
Companies Similar to VMD
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
TACTILE SYSTEMS TECHNOLOGY INC
Bioventus Inc.
NATURES SUNSHINE PRODUCTS INC
Electromed, Inc.
Pennant Group, Inc.
Addus HomeCare Corp
ANI PHARMACEUTICALS INC
IRADIMED CORP
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put VMD on your watchlist
Track score changes the day VIEMED HEALTHCARE, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VMD a good stock to buy?
13F Pro's AI-powered analysis of VIEMED HEALTHCARE, INC. (VMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VMD are available on the VMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VMD is classified as a small company.
Which hedge funds own VMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of VIEMED HEALTHCARE, INC.'s investment landscape.